Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Methotrexate versus expectant management for low-hCG ectopic pregnancy
NL-OMON25989Active, not recruiting
- Sponsor
- Amsterdam UMC, Department of Obstetrics and Gynaecology
- Start
- Jun 2006
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Open-label trial of methotrexate in Ectopic pregnancy (EP) and Pregnancy of unknown location (PUL) (2 arms), sponsored by Amsterdam UMC, Department of Obstetrics and Gynaecology. Primary endpoint: Uneventful decline of serum hCG to an undetectable level by primary treatment. Started Jun 2006; status: active, not recruiting.
02
Drugs
methotrexate
03
Conditions
Ectopic pregnancy (EP)Pregnancy of unknown location (PUL)
Beyond the preview
Go deeper on NL-OMON25989.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON25989.